Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Okamura N, Suemoto T, Shimadzu H, Suzuki M, Shiomitsu T, Akatsu H, Yamamoto T, Staufenbiel M, Yanai K, Arai H, Sasaki H, Kudo Y, Sawada T. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004 Mar 10;24(10):2535-41. PubMed Abstract

  
Comments on Paper and Primary News
  Primary News: Network Diagnostics: "Default-Mode" Brain Areas Identify Early AD

Comment by:  Randy Buckner
Submitted 28 March 2004  |  Permalink Posted 28 March 2004

Comment by Randy L. Buckner and Cindy Lustig
A major challenge to developing therapies for Alzheimer's disease is the availability of valid and robust diagnostic markers. Clinical assessment and cognitive testing have traditionally been the gold standard. Over the past decade, there has been an increasing emphasis on two categories of neuroimaging markers—those based on structural measures, and those based on metabolic measures. Greicius and colleagues, in their recent paper in the Proceedings of the National Academy of Sciences (2004), suggest a novel diagnostic marker for Alzheimer's disease, based on functional MRI measures.

Their work is based on the recent discovery of a "default network" that is ubiquitously observed in brain imaging studies of healthy, young participants (Raichle et al., 2001). Default network activity is observed during periods of rest and passive tasks that do not require targeted, effortful processing. Anticipating the work of Greicius and colleagues, it is...  Read more

  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:

Immunostaining was performed using monoclonal antibodies (mAbs) against Ab (6F/3D; Dako) at a dilution of 1:50: Ab1-40 (BA27; Wako), Ab1-42 (BC05; Wako), and Tau (pSer422; Wako).

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad